Details of the Drug Combinations

General Information of This Drug (ID: DMY85QW)

Drug Name

Bazedoxifene DMY85QW

Synonyms

Brilence; Conbriza; Viviant; Bazedoxifene acetate; TSE-424; WAY-140424; WAY-TES 424

Indication

Disease Entry	ICD 11	Status	REF
Hot flushes	GA30	Approved	[1]
Osteopetrosis	LD24.10	Approved	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Bazedoxifene + Panobinostat	DC7IKZU	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
------------------------------------------------------------------------------------

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Conjugated estrogens + Bazedoxifene	DCLC4NQ	Conjugated estrogens	Postmenopausal osteoporosis	[4]
------------------------------------------------------------------------------------

References

1	Bazedoxifene FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7355).
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4	Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol. 2013 May;121(5):959-68.